NasdaqGS:INSMBiotechs
Insmed (INSM) TPIP Data Keeps Bull Case Alive As Valuation Debate Builds
Why the latest TPIP data matters for Insmed stock
Insmed (INSM) is back in focus after releasing 12 month open label extension data for its treprostinil palmitil inhalation powder in pulmonary arterial hypertension, alongside a special call to walk investors through the results.
The update highlighted sustained effects on six minute walk distance, cardiac stress biomarkers, and World Health Organization Functional Class, together with a long term safety profile that management believes...